VenookA.P., WarrenR.S.: Regional chemotherapy
approaches for primary and metastatic liver tumors.
Surg Oncol Clin N Am, 5:
411–427, 1996.
2.
Meta-Analysis Group in
Cancer: Reappraisal of hepatic arterial infusion in
the treatment of nonresectable liver metastases from colorectal
cancer. J Natl Cancer Inst,
88: 252–258,
1996.
3.
YagodaA., PetrylakD., ThompsonS.: Cytotoxic chemotherapy
for advanced renal cell carcinoma. Urol Clin N
Am, 20: 303–321,
1993.
4.
MavligitG.M., ZukivskiA.A., GuttermanJ.U., SalemP., CharnsangavejC., WallaceS.: Splenic versus hepatic
artery infusion of interleukin-2 in patients with liver
metastases. J Clin Oncol,
8: 319–324,
1990.
5.
MelicharB., TouskovaM., BlahaM., VeselyP., DvorakJ., KrajinaA., CermanJ.: Hepatic arterial
administration of activated leukocytes in patients with liver
metastases. Cancer Biother Radiopharm,
17: 545–552,
2002.
6.
MelicharB., VoborilZ., CermanJ., MelicharovaK., MergancovaJ., VoborilR., JandikP.: Survival of patients
with colorectal cancer liver metastases treated by regional
chemotherapy. Hepatogastroenterology,
53: 422–430,
2006.
7.
BarkholtL., DanielssonR., CalissendorffB., SvenssonL., MalihiR., RembergerM., UzunelM., ThorneA., RingdenO.: Indium-111-labelled
donor-lymphocyte infusion by way of hepatic artery and radio-frequency
ablation against liver metastases of renal and colon carcinoma after
allogeneic hematopoietic stem-cell transplantation.
Transplantation, 78:
697–703, 2004.
McDermottD.F., ReganM.M., ClarkJ.I., FlahertyL.E., WeissG.R., LoganT.F., KirkwoodJ.M., GordonM.S., SosmanJ.A., ErnstoffM.S., TretterC.P.G., UrbaW.J., SmithJ.W., MargolinK.A., MierJ.W., GollobJ.A., DutcherJ.P., AtkinsM.B.: Randomized phase III
trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and
interferon in patients with metastatic renal cell carcinoma.
J Clin Oncol, 23:
133–141, 2005.
10.
YangJ.C., SherryR.M., SteinbergS.M., TopalianS.L.,
SchwartzentruberD.J., HwuP., SeippC.A.,
Rogers-FreezerL., MortonK.E., WhiteD.E., LiewehrD.J., MerinoM.J., RosenbergS.A.: Randomized study of
high-dose and low-dose interleukin-2 in patients with metastatic renal
cancer. J Clin Oncol, 21:
3127–3132, 2003.
11.
HulandE., HeinzerH., MirT.S., HulandH.: Inhaled interleukin-2
therapy in pulmonary metastatic renal cell carcinoma: Six years of
experience. Cancer J Sci Am,
3: S98–S105,
1997.
12.
WirthM.P.: Immunotherapy for
metastatic renal cell carcinoma. Urol Clin N
Am, 20: 283–295,
1993.
13.
Murray LawT., MotzerR.J., MazumdarM., SellK.W., WaltherP.J., O'ConnellM., KhanA., VlamisV., VogelzangN.J., BajorinD.F.: Phase III randomized
trial of interleukin-2 with or without lymphokine-activated killer cells in
the treatment of patients with advanced renal cell
carcinoma. Cancer, 76:
824–832, 1995.
14.
MotzerR.J., HutsonT.E., TomczakP., MichaelsonM.D., BukowskiR.M., RixeO., OudardS., NegrierS., SzcylikC., KimS.T., ChenI., BycottP.W., BaumC.M., FiglinR.A.: Sunitinib versus
interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med, 356:
115–124, 2007.
15.
ChildsR., ChernoffA., ContntinN., BahceciE., SchrumpD., LeitmanS., ReadE., TisdaleJ., DunbarC., LinehanW.M., YoungN.S., BarrettA.J.: Regression of
metastatic renal-cell carcinoma after nonmyeloablative allogeneic
peripheral-blood stem-cell transplantation. N Engl J
Med, 343: 750–758,
2000.
16.
RiniB.I., ZimmermanT., StadlerW.M., GajewskiT.F., VogelzangN.J.: Allogeneic stem-cell
transplantation of renal cell cancer after nonmyeloablative chemotherapy:
feasibility, engraftment, and clinical results. J
Clin Oncol, 20:
2017–2024, 2002.
